Soft tissues such as muscles, blood vessels, fat, tendons, and lining of the joints connect, support, and surround other body structures. Cancers that originate in these soft tissues are known as soft tissue sarcomas. There are more than 50 types of soft tissue sarcomas, including Kaposi sarcoma, Rhabdomyosarcoma, alveolar soft part sarcoma, adult fibrosarcoma, clear cell sarcoma, liposarcomas, and synovial sarcoma. Common types of soft tissue sarcomas include leiomyosarcoma, abdominal sarcoma, liposarcoma, and undifferentiated pleomorphic sarcoma. According to the American Cancer Society, more than 11,400 new cases of soft tissue sarcoma were diagnosed in the U.S. in 2014. The causes of soft tissue sarcoma are difficult to determine; however, exposure to certain chemicals such as phenoxyacetic herbicides and dioxins; previous exposure to radiotherapy; old age; and certain genetic conditions are anticipated to increase the risk of soft tissue sarcoma. Diagnostic methods used to detect soft tissue sarcoma include PET scan, biopsy, CT scan, and X-ray imaging.
Rise in incidence and prevalence of various types of soft tissue sarcomas, strong focus on research and development to enhance the treatment options available such as targeted therapies and biological therapies, large pipeline of drugs, growth in awareness among people, increase in approvals for the manufacture of generics, and rise in funding for research are some of the factors driving the market. However, side effects associated with cancer treatment, high cost of treatment, stringent government regulations, and high failure rate in clinical trials are likely to hamper the soft tissue sarcoma market in the near future. Additionally, significant shortage of doxorubicin, one of the major drugs employed in chemotherapy, has been reported by the U.S. FDA. The lack of reimbursement for a majority of the registered drugs under the public insurance programs and the lack of availability of many of the oncology drugs in some of the regions might hamper the future market growth.
The soft tissue sarcoma market can be segmented based on treatment type, end-user, and geography. In terms of the type of treatment, the market can be divided into chemotherapy, targeted therapy, radiation therapy, and surgery. The chemotherapy treatment segment of the soft tissue sarcoma market generally involves a combination of various anti-cancer drugs. Commonly used drugs include ifosfamide and doxorubicin. Other chemotherapy drugs include dacarbazine, cisplatin, oxaliplatin, paclitaxel, eribulin, and vincristine. Chemotherapy and targeted therapy segments are anticipated to dominate the soft tissue sarcoma market during the forecast period. In terms of end-user, the soft tissue sarcoma market can be classified into multi-specialty hospitals, cancer research centers, ambulatory surgical centers, and others. Multi-specialty hospitals are anticipated to remain dominant during the forecast period.
Based on geography, the soft tissue sarcoma market can be segmented into North America, Europe, Latin America, Asia Pacific, and Middle East & Africa. In terms of revenue, North America is anticipated to account for large share of the market during the forecast period. It is likely to be followed by the market in Europe. High incidence rate of soft tissue sarcomas, increase in awareness about soft tissue sarcoma, rise in focus on healthcare, and well-established healthcare infrastructure are some of the factors driving the market in North America. The soft tissue sarcoma market in Asia Pacific is estimated to expand at a high CAGR during the forecast period, led by the increase in government spending on healthcare services in India and China. The market in Latin America and Middle East & Africa is projected to expand during the forecast period, owing to the rise in investments by market players and increase in prevalence of soft tissue sarcomas.
Key players operating in the soft tissue sarcoma market include Genentech USA, Pfizer, Inc., Eli Lilly and Company, Bristol-Myers Squibb, Hoffmann-La Roche Ltd, Johnson & Johnson, Inc., GlaxoSmithKline, Teva Pharmaceuticals, and Celgene Corporation.
The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.
Request a brochure of this report to know what opportunities will emerge in the rapidly evolving Soft Tissue Sarcoma Market during 2017- 2025
Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.
Each TMR syndicated research report covers a different sector – such as pharmaceuticals, chemicals, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, TMR’s syndicated reports strive to provide clients to serve their overall research requirement.
US Office Contact
90 State Street, Suite 700
Albany, NY 12207
USA – Canada Toll Free: 866-552-3453